Showing results (21-30 of 72) with videos related to
Sort By:
Pageof 8
Digestive Diseases (Basel, Switzerland)|October 19, 2012
Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatmentMichael Trauner, Emina Halilbasic, Anna Baghdasaryan, et al.Digestive Diseases (Basel, Switzerland)|May 13, 2010
New insights into autoimmune cholangitis through animal modelsMichael Trauner, Peter Fickert, Anna Baghdasaryan, et al.Digestive Diseases (Basel, Switzerland)|July 11, 2015
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASHStefan Traussnigg, Christian Kienbacher, Emina Halilbasic, et al.Hepatology (Baltimore, Md.)|June 30, 2005
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in miceMartin Wagner, Emina Halilbasic, Hanns-Ulrich Marschall, et al.Journal of Magnetic Resonance Imaging : JMRI|July 5, 2021
Concentration of Gallbladder Phosphatidylcholine in Cholangiopathies: A Phosphorus-31 Magnetic Resonance Spectroscopy Pilot StudyLorenz Pfleger, Emina Halilbasic, Martin Gajdošík, et al.Journal of Pharmaceutical Sciences|February 9, 2016
Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in MiceThomas Wanek, Emina Halilbasic, Michele Visentin, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 10, 2020
Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver diseaseRafael Paternostro, Stefan Traussnigg, Katharina Staufer, et al.The Journal of Nutritional Biochemistry|October 23, 2023
Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunctionAnnette Brandt, Katja Csarmann, Angélica Hernández-Arriaga, et al.Alimentary Pharmacology & Therapeutics|February 27, 2024
Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosisBenedikt Silvester Hofer, Lukas Burghart, Emina Halilbasic, et al.Wiener Klinische Wochenschrift|September 15, 2020
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver diseaseStefan Traussnigg, Emina Halilbasic, Harald Hofer, et al.Pageof 8